Transaction #16601 · Form 4 · 0001104659-25-119320
CRESCENT BIOPHARMA, INC. · Purchase · Ordinary Shares
CRESCENT BIOPHARMA, INC. · Transacted December 4, 2025 · Filed December 8, 2025
What does this filing report?
An SEC Form 4 filing for CRESCENT BIOPHARMA, INC. records a purchase involving Ordinary Shares on December 4, 2025. The reported quantity was 1,360,000. The filing date is December 8, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- CRESCENT BIOPHARMA, INC.
- Company CIK
- 0001253689
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 1,360,000
- Reported price
- 13.41
- Reference value
- 18,237,600
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 2,747,866
- Ownership description
- By Fairmount Healthcare Fund II L.P.
- SEC acceptance time
- Dec 8, 2025, 4:30 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Harwin Peter Evan ↗
Director · 10% owner
CIK 0001663607
- Fairmount Healthcare Fund II L.P. ↗
Director · 10% owner
CIK 0001769651
- Fairmount Funds Management LLC ↗
Director · 10% owner
CIK 0001802528
- Kiselak Tomas ↗
Director · 10% owner
CIK 0001830177
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- F2
- The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise.
Remarks
Fairmount may be deemed a director by deputization of Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.